Prince of Wales Hospital
Hong Kong
Location status: Recruiting
Location contact
Kate Ching Ching Chan, MD
CONTACT
Kate Ching Ching Chan, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05115968
Obstructive sleep apnoea (OSA) in children is a prevalent sleep disorder, and is characterised by repetitive complete or partial upper airway obstruction during sleep. It is an important disease as it is associated with a large spectrum of end-organ morbidities.
Adenotonsillar hypertrophy is the commonest cause of OSA in children, however, the cause of the lymphoid tissue hypertrophy in some individuals but not the others remains unknown. To address the cellular heterogeneity and immune cell involvement in adenotonsillar hypertrophy, here, we propose to employ single-cell sequencing analysis to identify the cell-specific expression patterns associated with the disease, which will enhance our understanding of the pathogenesis of tonsillar hypertrophy in children with OSA and may provide directions for development of novel therapy.
Interested in participating?
Request Info6 year–11 year
All sexes
Observational
Hong Kong
Location status: Recruiting
Kate Ching Ching Chan, MD
CONTACT
Kate Ching Ching Chan, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Case: Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases.
Control: Non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
Exclusion criteria
Previous upper airway surgery, genetic or syndromal disease, congenital or acquired neuromuscular disease, congenital or acquired immunodeficiency, known metabolic syndrome, craniofacial abnormalities.
Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
Time frame: Through study completion, an average of 2 years
Cells characteristics by single-cell sequencing of the adenotonsillar tissue in children with OSA.
Contact information is provided by the study sponsor or research team.
Elly Cheung
CONTACT
Kate C Chan, MBChB
CONTACT
Chinese University of Hong Kong
Other
Single Cell Sequencing to Examine the Pathogenesis of Adenotonsillar Hypertrophy in Children With Obstructive Sleep Apnoea
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07380321
Obstructive Sleep Apnea of Child
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsNCT07345312
Obstructive Sleep Apnea of Child
Nancy, Grand Est, France
View Trial DetailsNCT06634264
Adenotonsillar Hypertrophy, Apnea
Montreal, Quebec, Canada
View Trial DetailsNCT06367400
Apnea, Dyssomnias
Uppsala, Sweden
View Trial Details